Telomerase activity and survival of late-stage South African esophageal carcinoma patients

Diseases of the Esophagus

Volumn 17, Issue 3, 2004, Pages 251-256

  van den Heever, W M J ^a   Pretorius, G H J ^a   Smit, S J A ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

Epithelium; Field cancerization; Gastroscopy

Indexed keywords

TELOMERASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SOUTH AFRICA; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PROGNOSIS; SOUTH AFRICA; SURVIVAL ANALYSIS; TELOMERASE;

EID: 5744237843     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2004.00417.x     Document Type: Article

References (30)

1. Flood W A, Forastiere A A. Esophageal cancer. Curr Opin Oncol 1995; 7: 381-6.
2. Sitas F. National Cancer Registry of South Africa. Annual statistical report for 1988. Johannesburg: South African Institute for Medical Research, 1992.
3. Marasas W F O, Jaskiewicz K, Venter F S, Van Schalkwyk D J. Fusarium moniliforme contamination of maize in esophageal cancer areas in Transkei. S Afr Med J 1988; 74: 110-14.
4. Jaskiewiecz K, Marasas W F, Rossouw J E, Van Niekerk F E, Heine Tech E W. Selenium and other mineral elements in populations at risk for esophageal cancer. Cancer 1988; 12: 2635-9.
5. Rheeder J P, Marasas W F, Farina M P, Thompson G R, Nelson P E. Soil fertility factors in relation to oesophageal cancer risk areas in Transkei, Southern Africa. Eur J Cancer Prev 1994; 1: 49-56.
6. Gamielden W G, Victor T C, Mugwanya D et al. P53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. Int J Cancer 1998; 78: 544-9.
7. Maesawa C, Tamura G, Suzuki Y et al. Aberrations of tumor-suppressor genes (p53, apc, mcc and Rb) in esophageal squamous-cell carcinoma. Int J Cancer 1994; 57: 21-5.
8. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993; 119: 441-9.
9. Blacburn E H. Telomerases. Annu Rev Biochem 1992; 61: 113-29.
10. Collins K, Mitchell J R. Telomerase in the human organism. Oncogene 2002; 21: 564-79.
11. Hiyama K, Hirai Y, Kyoizumi S et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995; 8: 3711-15.
12. Taylor R S, Ramirez R D, Ogoshi M, Chaffins M, Piatyszek M A, Shay J W. Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol 1996; 106: 759-65.
13. Yasumoto S, Kunimura C, Kikuchi K et al. Telomerase activity in normal human eptihelial cells. Oncogene 1996; 13: 433-9.
14. Mutirangura A, Supiyaphun P, Trirekapan S et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3530-3.
15. Sommerfeld H-J, Meeker A K, Piatyszek M A, Bova G S, Shay J W, Coffey D S. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996; 56: 218-22.
16. Hiyama E, Gollahon L, Kataoka T et al. Telomerase activity in human breast tumors. J Natl Cancer Inst 1996; 88: 116-22.
17. Umbricht C B, Sherman M E, Dome J et al. Telomerase activity in ductal carcinoma in situ and invasive breast cancer. Oncogene 1999; 18: 3407-14.
18. Muller M, Heine B, Heicappel R et al. Telomerase activity in bladder cancer, bladder washings and in urine. Int J Oncol 1996; 9: 1169-73.
19. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek M A, Shay J W. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995; 1: 249-55.
20. Takubo K, Nakamura K-I, Izumiyama N et al. Telomerase activity in esophageal carcinoma. J Surg Oncol 1997; 66: 88-92.
21. Morales C P, Lee E L, Shay J W. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's oesophagus to esophageal adenocarcinoma. Cancer 1998; 83: 652-9.
22. Bryan T M, Marusic L, Bachetti S, Namba M, Reddel R R. The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit. Hum Mol Genet 1997; 6: 921-6.
23. Herbert B S, Pitts A E, Baker S I et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999; 96: 14276-81.
24. Corey D R. Telomerase inhibition, oligonucleotides and clinical trials. Oncogene 2002; 21: 631-7.
25. Kim N W, Piatyszek M A, Prowse K R et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-15.
26. Wright W E, Shay J W, Piatyszek M A. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucl Acids Res 1995; 23: 3794-5.
27. Yokota K, Kanda K, Inouhe Y, Kanayama H, Karawa S. Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. Br J Surg 1998; 82: 727-32.
28. Koyanagi K, Ozawa S, Ando N, Takeuchi H, Ueda M, Kitajima M. Clinical significance of telomerase activity in the non-cancerous epithelial region of esophageal squamous cell carcinoma. Br J Surg 1999; 86: 674-9.
29. Hiyama T, Yokazaki H, Kitadai Y et al. Overexpression of human telomerase RNA is an early event in esophageal carcinogenesis. Virchows Arch 1999; 434: 483-7.
30. Koyanagi K, Ozawa S, Ando N, et al. Telomerase activity as an indicator of malignant potential in iodine-nonreactive lesions of the oesophagus. Cancer 2000; 7: 1524-9.